Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.
暂无分享,去创建一个
R. Gascoyne | L. Sehn | J. Connors | J. Spinelli | N. Macpherson | R. Klasa | K. Gill | M. Chhanabhai | K. Wilson | J. Donaldson | S. O'Reilly | C. Fitzgerald | J. Sutherland | Karamjit K. Gill
[1] M. Pfreundschuh,et al. Randomized intergroup trial of first line treatment for patients <=60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab -early stopping after the first interim analysis. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] B. E. C. Oiffier,et al. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .
[3] S. Boehrer,et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. , 2002, Haematologica.
[4] J. Vose,et al. Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] L. Gordon,et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] V. Diehl,et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. , 1998, Blood.
[7] R. Levy,et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Gascoyne,et al. Advanced diffuse large-cell lymphoma treated with 12-week combination chemotherapy: natural history of relapse after initial complete response and prognostic variables defining outcome after relapse. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] A. Demidem,et al. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. , 1997, Cancer biotherapy & radiopharmaceuticals.
[10] D. R. Anderson,et al. Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. , 1997, Biochemical Society transactions.
[11] P. Chinn,et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.
[12] Emili Montserrat,et al. A predictive model for aggressive non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[13] T M Grogan,et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.
[14] J. Connors,et al. MACOP-B and VACOP-B in diffuse large cell lymphomas and MOPP/ABV in Hodgkin's disease. , 1991, Annals of oncology : official journal of the European Society for Medical Oncology.
[15] J. Connors,et al. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.
[16] C. Coltman,et al. Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma , 1976, Cancer.
[17] D. Cox. Regression Models and Life-Tables , 1972 .
[18] N. Mantel. Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.
[19] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .